1 streaming video file (100 min.) : sd., col.
Encoded with permission for digital streaming by Films Media Group on August 01, 2014.
Films on Demand is distributed by Films Media Group for Films for the Humanities & Sciences, Cambridge Educational, Meridian Education, and Shopware.
Intelligence Squared U.S., the Oxford style, three-on-three debate series is produced by the Rosenkranz Foundation in New York City. These debates are produced for radio by WNYC, New York Public Radio, and distributed nationally by NPR. The programs reach a wide audience and attract as speakers the top experts, specialists and passionate advocates for both sides of each issue.
Intro: FDA Debate (3:40) -- FDA Debate "Housekeeping" (5:54) -- For the Motion: Dr. Scott Gottlieb (7:03) -- Against the Motion: Dr. Jerry Avorn (6:40) -- For the Motion: Peter Hubert (7:49) -- Against the Motion: Dr. David Challoner (7:49) -- Understanding FDA Drug Trials (4:27) -- FDA Fast Track (3:57) -- Accelerated Approval and Public Safety (2:06) -- FDA Uncertainty (3:10) -- FDA's Role (4:03) -- FDA Approval Rates (3:10) -- Accelerated Drug Approval Ethics (4:57) -- FDA Conflict of Interest (2:21) -- QA: Unsafe Drug Approval (3:44) -- QA: Public vs. Individual Health (3:09) -- QA: Side Effect Uncertainty (3:23) -- QA: Prescribing Drug Cocktails (1:53) -- QA: Bayesian Statistical Model (2:27) -- QA: Drug Industry Financing FDA (3:02) -- QA: Promoting Drug Development (1:32) -- QA: FDA Precautionary Principle (4:46) -- Closing Statement Against: Jerry Avorn (2:29) -- Closing Statement For: Scott Gottlieb (1:42) -- Closing Statement Against: David Challoner (1:56) -- Closing Statement For: Peter Huber (2:30) -- Audience Vote Results (1:42) -- Credits: The FDA's Caution Is Hazardous to Our Health: A Debate (0:44)
Access requires authentication through Films on Demand.
Established in 1906, the U.S. Food and Drug Administratio? (FDA) is charged with protecting public health. Under this mandate, the federal agency regulates drugs and medical devices to ensure their safety and effectiveness. But is the FDA failing this mandate? Some argue that the FDA's long and costly approval process stifles innovation and keeps life-changing treatments from the market, but defenders contend that the process is essential to ensure safety and protect public health. Is the FDA too cautious in approving new drugs and medical devices? Is it ever appropriate to sacrifice safety for speed?
10 & up.
Mode of access: Internet.
System requirements: FOD playback platform.
Title from distributor's description.
Films for the Humanities (Firm)
Films Media Group.
Select "Continue session" to extend your session.